Peripheral T-cell lymphoma: From biology to practice to the future

医学 外周T细胞淋巴瘤 淋巴瘤 外围设备 计算生物学 癌症研究 免疫学 内科学 T细胞 免疫系统 生物
作者
Owen A. O’Connor,Helen Ma,Jason Yongsheng Chan,Seok Jin Kim,Sang Eun Yoon,Won-Seog Kim
出处
期刊:Cancer Treatment Reviews [Elsevier]
卷期号:: 102793-102793
标识
DOI:10.1016/j.ctrv.2024.102793
摘要

Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and broaden our perspective, highlighting their diverse nature and the varying molecular mechanisms underlying the entities. Based on a comprehensive accumulated understanding, the PTCLs currently overcome the most challenging features of any disease: rarity, incredible heterogeneity, and a lack of any established standard of care. The treatments deployed in the front-line are extrapolated from regimens developed for other diseases. The recent approval of the three drugs brentuximab vedotin (BV), pralatrexate, and belinostat for patients with relapsed or refractory disease has provided clues about pathophysiology and future directions, though challenges satisfying post-marketing requirements (PMR) for those accelerated approvals have led to one of those drugs being withdrawn and put the other two in jeopardy. Edits of the front-line regimens, often called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-plus approaches, look more like CHOP-minus strategies, as the toxicity of five-drug regimens often reduces the dose intensity of the added 'novel' drug, nullifying any hope of an advance. The turmoil in the field produced by the aforementioned, coupled with an ever-changing classification, has left the field uncertain about the path forward. Despite these challenges, empiric findings from studies of novel drug approaches, coupled with a logic emerging from studies of PTCL lymphomagenesis, have begun to illuminate, albeit faintly for some, a potential direction. The empiric finding that drugs targeting the discrete components of the PTCL epigenome, coupled with the description of multiple mutations in genes that govern epigenetic biology, offers, at the very least, an opportunity to finally be hypothesis-driven. The most recent recognition that the only combination of drugs shown to markedly improve progression-free survival (PFS) in patients with relapsed disease is one based on dual targeting of different and discrete components of that epigenetic biology has established a possibility that circumnavigating chemotherapy addition studies is both plausible, feasible, and likely the best prospect for a quantum advance in this disease. Herein, we analyze PTCL through a 2025 lens, highlighting and underscoring walls that have impeded progress. We will critically explore all the clues and the panoramic view of PTCL research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蒸蒸日上发布了新的文献求助10
刚刚
文森特的向日葵完成签到,获得积分10
1秒前
单薄绮露完成签到,获得积分10
3秒前
米莉森的锋刃完成签到,获得积分10
3秒前
充电宝应助LLL采纳,获得10
5秒前
5秒前
bkagyin应助自信号厂采纳,获得10
7秒前
JSM发布了新的文献求助500
7秒前
7秒前
迷人的跳跳糖完成签到,获得积分10
9秒前
橘子完成签到,获得积分10
10秒前
11秒前
传奇3应助蒸蒸日上采纳,获得10
12秒前
库里强发布了新的文献求助10
12秒前
13秒前
14秒前
14秒前
14秒前
zzz发布了新的文献求助10
15秒前
ElbingX发布了新的文献求助50
16秒前
17秒前
18秒前
晓昀发布了新的文献求助10
18秒前
19秒前
鸢尾应助狂野的白开水采纳,获得10
19秒前
19秒前
20秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
天天快乐应助科研通管家采纳,获得10
20秒前
tfq200发布了新的文献求助10
20秒前
orixero应助科研通管家采纳,获得10
20秒前
领导范儿应助科研通管家采纳,获得10
20秒前
深情安青应助科研通管家采纳,获得10
20秒前
20秒前
CipherSage应助科研通管家采纳,获得10
20秒前
zqh应助科研通管家采纳,获得10
20秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
20秒前
21秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3071903
求助须知:如何正确求助?哪些是违规求助? 2725788
关于积分的说明 7491264
捐赠科研通 2373147
什么是DOI,文献DOI怎么找? 1258476
科研通“疑难数据库(出版商)”最低求助积分说明 610277
版权声明 596944